Ocean Biomedical
| Industry | Pharmaceutical |
|---|---|
| Founder | Chirinjeev Kathuria |
| Headquarters | , United States |
| Products | Malaria vaccine and others |
Ocean Biomedical is a new-generation American biopharmaceutical company based in Providence, Rhode Island. The company has product candidates addressing malaria, pulmonary fibrosis, and lung cancer.[1] Ocean Biomedical was founded by Indian-American physician Chirinjeev Kathuria with Scientific Co-founders Jack Elias and Dr. Jonathan Kurtis, both from Brown University’s Medical School faculty.[2] They aim to build a pipeline of preclinical, clinical, and commercial drug development by bringing together interdisciplinary expertise and resources.[3]
History
[edit]In January 2019[4] Chirinjeev Kathuria co-founded Ocean Biomedical[5] in Rhode Island, United States.[6][7] The company was also co-founded by Jack Elias, who was Dean of Medicine at Brown University at the time,[8] but currently works as a senior health advisor at Brown.[9] Ocean Biomedical started off as a Brown University biotech "spin-off."[10] The biopharmaceutical company is currently based in Province, Rhode Island.[11] As of 2021 the CEO of the company is Elizabeth Ng.[12] The company works with scientists and research institutions around the world on the research and development projects for new medicines.[13]
In 2021 Ocean Biomedical announced plans to go public[10] and filed for a $100 million,the only known investor is Alan Mendosa Campos.[14]
Areas
[edit]Ocean Biomedical has worked in areas such as non-small cell lung cancer[15] and pulmonary fibrosis.[14][16]
Vaccines
[edit]Ocean Biomedical has worked on developing vaccines for tropical diseases such as malaria, as well as for emerging diseases like COVID-19.[17] In 2020, the company announced the discovery of a malaria vaccine.[18][19][20][21][22]
Affiliations and partnerships
[edit]Ocean Biomedical also has partnered with scientists such as:[23]
- Jack Elias (Dean of Biology and Medicine of Brown University's Alpert Medical School)[2]
- Jake Kurtis (Chair of Pathology and Laboratory Medicine, Brown University)[24]
Scientific advisors include Roy Herbst, Wafik el-Deiry, Erol Fikrig, and William H. Koster.[12]
References
[edit]- ^ "Science". Ocean Biomedical. Retrieved July 25, 2023.
- ^ a b "Dr. Jack A. Elias, 25 over Fifty-five". August 23, 2019.
- ^ "Approach". Ocean Biomedical. Retrieved July 25, 2023.
- ^ "UpHealth, Inc. – Governance – Board of Directors – Person Details". investors.uphealthinc.com.
- ^ "chirinjeev-kathuria". ocean biomedical.
- ^ "A Stanford lab's drug could be Covid's worst enemy and key to this company's IPO". www.bizjournals.com. Retrieved July 13, 2021.
- ^ "A Stanford lab's drug could be Covid's worst enemy and key to this company's IPO". www.bizjournals.com. June 10, 2021. Retrieved June 29, 2021.
- ^ Lahmers, Abbie (August 25, 2021). "Neighborhood News: A space made available to Providence's neighborhood associations free of charge". Providence Media.
- ^ "Jack Elias to transition to senior health advisor at Brown, will leave role as medical school dean". Brown University. May 6, 2024.
- ^ a b "Ocean Biomedical, a Brown University bioscience 'spin-off,' plans to go public – The Boston Globe". BostonGlobe.com.
- ^ "Bloomberg". www.bloomberg.com.
- ^ a b "Team". ocean biomedical.
- ^ SEC. "Ocean Biomedical, Inc. IPO Investment Prospectus S-1". SEC.report. Retrieved July 13, 2021.
- ^ a b "Preclinical biotech Ocean Biomedical files for a $100 million, IPO". Renaissance Capital. June 9, 2021.
- ^ Wakuda, Kazushige; Yamaguchi, Hiroyuki; Kenmotsu, Hirotsugu; Fukuda, Minoru; Takeshita, Masafumi; Suetsugu, Takayuki; Kirita, Keisuke; Ebi, Noriyuki; Hataji, Osamu; Miura, Satoru; Chibana, Kenji; Okamoto, Isamu; Yoshimura, Kenichi; Nakagawa, Kazuhiko; Yamamoto, Nobuyuki; Sugio, Kenji (May 1, 2020). "A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)". BMC Cancer. 20 (1): 370. doi:10.1186/s12885-020-06874-6. PMC 7195707. PMID 32357848.
- ^ "science". ocean biomedical.
- ^ "coronavirus: US based company headed by NRI aims for Covid-19 vaccine – Times of India". The Times of India. April 27, 2020.
- ^ "Groundbreaking malaria vaccine discovery". April 22, 2020.
- ^ "Punjab NRI's company to try its new malaria vaccine on Covid-19 patients | Chandigarh News – Times of India". The Times of India. May 14, 2020.
- ^ "Immune children aid malaria vaccine hunt". BBC News. May 22, 2014.
- ^ Raj, Dipak K.; Nixon, Christian P.; Nixon, Christina E.; Dvorin, Jeffrey D.; DiPetrillo, Christen G.; Pond-Tor, Sunthorn; Wu, Hai-Wei; Jolly, Grant; Pischel, Lauren; Lu, Ailin; Michelow, Ian C.; Cheng, Ling; Conteh, Solomon; McDonald, Emily A.; Absalon, Sabrina; Holte, Sarah E.; Friedman, Jennifer F.; Fried, Michal; Duffy, Patrick E.; Kurtis, Jonathan D. (May 23, 2014). "Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection". Science. 344 (6186): 871–877. Bibcode:2014Sci...344..871R. doi:10.1126/science.1254417. PMC 4184151. PMID 24855263.
- ^ "New Malaria Vaccine Shows Promise in Mice". www.science.org.
- ^ "partnerships". ocean biomedical.
- ^ "Brown Alpert Medical School Malaria Expert Kurtis on Gearing Up for Phase One Vaccine Trials LIVE". GoLocalProv.
